JP2018523673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523673A5 JP2018523673A5 JP2018507602A JP2018507602A JP2018523673A5 JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5 JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5
- Authority
- JP
- Japan
- Prior art keywords
- hcab
- pdgf
- seq
- amino acid
- specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 108010081589 Becaplermin Proteins 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 13
- 208000001344 Macular Edema Diseases 0.000 claims 7
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 6
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 4
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 201000000159 corneal neovascularization Diseases 0.000 claims 4
- 201000010206 cystoid macular edema Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 206010025415 Macular oedema Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 201000010230 macular retinal edema Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 2
- 206010038886 Retinal oedema Diseases 0.000 claims 2
- 206010040925 Skin striae Diseases 0.000 claims 2
- 201000011666 conjunctival pterygium Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205191P | 2015-08-14 | 2015-08-14 | |
| US62/205,191 | 2015-08-14 | ||
| US201662333772P | 2016-05-09 | 2016-05-09 | |
| US62/333,772 | 2016-05-09 | ||
| PCT/US2016/046595 WO2017030909A1 (en) | 2015-08-14 | 2016-08-11 | Heavy chain only antibodies to pdgf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523673A JP2018523673A (ja) | 2018-08-23 |
| JP2018523673A5 true JP2018523673A5 (cg-RX-API-DMAC7.html) | 2019-08-22 |
Family
ID=56740535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507602A Pending JP2018523673A (ja) | 2015-08-14 | 2016-08-11 | Ｐｄｇｆに対する重鎖のみ抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US10308711B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3334762A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018523673A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016307943A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2992788A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1254093A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017030909A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| JP6916776B2 (ja) * | 2015-07-29 | 2021-08-11 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｎｇ−２に対する重鎖のみ抗体 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| SI1325932T1 (cg-RX-API-DMAC7.html) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US7090681B2 (en) | 2002-09-18 | 2006-08-15 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| ES2523661T3 (es) | 2004-07-22 | 2014-11-28 | Erasmus University Medical Center Rotterdam | Moléculas de unión |
| CA2632094C (en) * | 2005-12-02 | 2015-01-27 | Wayne A. Marasco | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| RU2435784C2 (ru) | 2006-01-25 | 2011-12-10 | Эрасмус Юниверсити Медикал Сентр Роттердам | Получение антител из одних тяжелых цепей в трансгенных животных |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
| EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| PH12013500333A1 (en) * | 2010-08-20 | 2013-04-22 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| HK1200468A1 (en) * | 2011-09-30 | 2015-08-07 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9428577B2 (en) * | 2012-11-09 | 2016-08-30 | Pfizer Inc. | Platelet-derived growth factor B specific antibodies and compositions and uses thereof |
| EP2917237A1 (en) * | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
| WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| JP6916776B2 (ja) * | 2015-07-29 | 2021-08-11 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｎｇ−２に対する重鎖のみ抗体 |
-
2016
- 2016-08-11 EP EP16754101.0A patent/EP3334762A1/en not_active Withdrawn
- 2016-08-11 HK HK18113157.2A patent/HK1254093A1/zh unknown
- 2016-08-11 JP JP2018507602A patent/JP2018523673A/ja active Pending
- 2016-08-11 WO PCT/US2016/046595 patent/WO2017030909A1/en not_active Ceased
- 2016-08-11 US US15/234,817 patent/US10308711B2/en active Active
- 2016-08-11 AU AU2016307943A patent/AU2016307943A1/en not_active Abandoned
- 2016-08-11 CA CA2992788A patent/CA2992788A1/en not_active Abandoned
-
2019
- 2019-05-29 US US16/425,140 patent/US11028163B2/en active Active
-
2021
- 2021-06-07 US US17/341,325 patent/US20220098295A1/en not_active Abandoned
-
2023
- 2023-05-24 US US18/322,927 patent/US20240043518A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,167 patent/US20250333490A1/en active Pending